Efficacy of Sofosbuvir Plus Ribavirin with or Without Peginterferon- Alfa in Treatment of a Cohort of Egyptian Patients with Hepatitis C Virus Infection

Ahmed, Ossama Ashraf; Kaisar, Hany Haroun; Hawash, Nehad; Samir, Hossam; S, Shabana; Fouad, Mohamed Hassan Ahmed; Rizk, Fatma H; Abd-Elsalam, Sherief

doi:10.2174/1871526517666170417143216

Cited by 34 publications

(22 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…HCV genotype 4 infection is common in the Middle East, Northern Africa, and Sub-Saharan Africa. In Egypt, 15% of an estimated population of 80 million is HCV positive, of which 93% are infected with genotype 4 [ 1 – 5 ].…”

Section: Introductionmentioning

confidence: 99%

Sofosbuvir Plus Daclatasvir in Treatment of Chronic Hepatitis C Genotype 4 Infection in a Cohort of Egyptian Patients: An Experiment the Size of Egyptian Village

Ahmed

Safwat

Khalifa

et al. 2018

International Journal of Hepatology

Self Cite

View full text Add to dashboard Cite

Background and Aims As indicated by the World Health Organization (WHO), Egypt is positioned as the country with the world's highest prevalence of Hepatitis C virus (HCV). HCV is transmitted through unexamined blood transfusions, different employments of syringes, and poor cleansing, as per the WHO. Our study aimed at screening and management of chronic hepatitis C genotype 4 infected patients in Bardeen village, Sharkeya Governorate, Egypt, with Sofosbuvir plus Daclatasvir, as well as estimating the safety and efficacy of that regimen. Methods Screening of adult patients in Bardeen village was done from March 2016 till November 2016 using hepatitis C virus antibodies by third-generation ELISA testing. Positive results were confirmed by PCR. Patients eligible for treatment received Sofosbuvir 400 mg and Daclatasvir 60 mg daily for 12 weeks and were assessed for sustained virologic response at 12 weeks following the end of treatment (SVR 12). Results Out of 2047 subjects screened for hepatitis C virus, 249 (12.2%) showed positive results. 221 out of those 249 subjects (88.7%) had detectable RNA by PCR. Treatment of eligible patients (183 patients) with Sofosbuvir plus Daclatasvir for 12 weeks resulted in 96% achievement of sustained virologic response at week 12. Adverse events were tolerable. Conclusion Sofosbuvir plus Daclatasvir regimen is safe and effective for treatment of chronic hepatitis C Genotype 4 infected patients with minimal adverse events. HCV eradication program implemented in Egypt can be a model for other countries with HCV and limited resources. The availability of generic drugs in Egypt will help much in eradication of the virus.

show abstract

Section: Introductionmentioning

confidence: 99%

Sofosbuvir Plus Daclatasvir in Treatment of Chronic Hepatitis C Genotype 4 Infection in a Cohort of Egyptian Patients: An Experiment the Size of Egyptian Village

Ahmed

Safwat

Khalifa

et al. 2018

International Journal of Hepatology

Self Cite

View full text Add to dashboard Cite

show abstract

“… 3 – 5 In Egypt, 15% of an estimated population of 85 million are HCV positive, of whom >90% are infected with genotype 4 (GT 4). 6 , 7 The rapid emergence of the epidemic in Egypt was initially fueled by the mass treatment of schistosomiasis using the injectable drug tartar emetic at some stage during the 1960s and 1970s. 8 …”

Section: Introductionmentioning

confidence: 99%

Efficacy and safety of sofosbuvir–ledipasvir for treatment of a cohort of Egyptian patients with chronic hepatitis C genotype 4 infection

Ahmed¹,

Kaisar²,

Badawi³

et al. 2018

IDR

Self Cite

View full text Add to dashboard Cite

Background and aimsTreatment of hepatitis C virus (HCV) infection has significantly changed during the last few years. The combination of ledipasvir and sofosbuvir has been shown to treat high proportions of patients with HCV genotype 1 with remarkable tolerability. The aim of the work was to assess the efficacy and safety of sofosbuvir plus ledipasvir in treating treatment-naïve Egyptian patients with genotype 4 HCV infection.Patients and methodsIn this open-label randomized study, 200 treatment-naive patients who were HCV antibody positive and HCV RNA positive by polymerase chain reaction, aged >18 years, were enrolled. The patients were classified into two groups: group I included 100 patients who received single therapy with sofosbuvir plus ledipasvir for 12 weeks and group II included 100 patients who received sofosbuvir plus oral weight-based ribavirin for 24 weeks. The primary end point was a sustained virological response at 12 weeks (SVR12) after the end of treatment, determined by quantitative polymerase chain reaction for HCV RNA.ResultsGroup I patients showed statistically significant (p<0.05) higher SVR12 compared with group II patients (99% vs. 80%). There was no statistical difference (p>0.05%) between the studied groups regarding the frequencies of the side effects (26% vs. 29%). The most common adverse effects were headache, fatigue, myalgia, and cough.ConclusionSofosbuvir and ledipasvir treatment for 12 weeks was well tolerated by patients with HCV genotype 4 and resulted in 99% SVR for all patients who received 12 weeks of the study drugs. ClinicalTrials.gov Identifier: NCT02992457.

show abstract

“…proximately 13% of all HCV infections worldwide, 1 with the highest prevalence occurring in Egypt (93% of genotype 4 worldwide and 15% of Egyptians), 2,3 where it is a leading cause of liver cirrhosis, hepatic cell carcinoma (HCC) and mortality. 4 Liver transplant (LT) has become a frequently used treatment strategy for end-stage liver disease (ESLD), HCC and acute liver failure, as it provides the only possibility of cure, long-term survival and improved quality of life.…”

Section: Chronichepatitis C Virus (Hcv) Infection Genotype 4 Occurs Imentioning

confidence: 99%

Effect of cyclosporine A versus tacrolimus on the response to antiviral therapy after hepatitis C genotype‐4 recurrence post–liver transplantation: A prospective cohort trial

et al. 2019

View full text Add to dashboard Cite

Summary What is known and objective The influence of immunosuppression on the response to antiviral therapy (AVT) for recurrent hepatitis C virus (HCV) infection in liver transplant (LT) recipients remains controversial, especially for the rarely investigated genotype 4. This study aims to compare the effects of the two widely used calcineurin inhibitors (CNIs) (cyclosporine A (CsA) and tacrolimus (Tac)) on the therapeutic response to different AVT regimens. Methods A prospective, dual‐centre, cohort study of 126 Egyptian living donor liver transplant (LDLT) recipients with recurrent HCV genotype 4 infection, who were categorized into three groups according to the AVT used. Group I received pegylated interferon (Peg‐IFN‐α 2a) plus ribavirin (RBV) (n = 44), group II received the direct antiviral agent (DAA) sofosbuvir plus RBV (n = 52) and group III received daclatasvir and sofosbuvir (also DAAs) plus RBV (n = 30). Each group was further subdivided according to the primary immunosuppression (CsA or Tac). The sustained virological response (SVR) and relapse rates were considered the primary therapeutic outcomes of AVT. Results No significant intergroup differences were observed in the achievement of primary and secondary outcomes. SVR rates in the IFN‐based regimen were 75% and 66.7% in CsA and Tac users and 81.2% and 83% in DAAs, respectively. Relapse rates in the IFN‐based regimen were 10% and 16.7% in CsA and Tac users and 12.5% and 14.9% in DAAs, respectively. What is new and conclusion Within the limitations of a relatively small study, CsA did not offer an advantage over Tac regarding the response to AVT after HCV genotype 4 recurrence in LDLT recipients.

show abstract

Efficacy of Sofosbuvir Plus Ribavirin with or Without Peginterferon- Alfa in Treatment of a Cohort of Egyptian Patients with Hepatitis C Virus Infection

Abstract: The triple regimen of Pegylated interferon, sofosbuvir plus ribavirin is safe and effective in the treatment of Egyptian patients with hepatitis C virus as well as sofosbuvir and ribavirin alone wit.

Cited by 34 publications

References 0 publications

Sofosbuvir Plus Daclatasvir in Treatment of Chronic Hepatitis C Genotype 4 Infection in a Cohort of Egyptian Patients: An Experiment the Size of Egyptian Village

Sofosbuvir Plus Daclatasvir in Treatment of Chronic Hepatitis C Genotype 4 Infection in a Cohort of Egyptian Patients: An Experiment the Size of Egyptian Village

Efficacy and safety of sofosbuvir–ledipasvir for treatment of a cohort of Egyptian patients with chronic hepatitis C genotype 4 infection

Effect of cyclosporine A versus tacrolimus on the response to antiviral therapy after hepatitis C genotype‐4 recurrence post–liver transplantation: A prospective cohort trial

Contact Info

Product

Resources

About

Efficacy of Sofosbuvir Plus Ribavirin with or Without Peginterferon- Alfa in Treatment of a Cohort of Egyptian Patients with Hepatitis C Virus Infection

Abstract: The triple regimen of Pegylated interferon, sofosbuvir plus ribavirin is safe and effective in the treatment of Egyptian patients with hepatitis C virus as well as sofosbuvir and ribavirin alone wit.

Cited by 34 publications

References 0 publications

Sofosbuvir Plus Daclatasvir in Treatment of Chronic Hepatitis C Genotype 4 Infection in a Cohort of Egyptian Patients: An Experiment the Size of Egyptian Village

Sofosbuvir Plus Daclatasvir in Treatment of Chronic Hepatitis C Genotype 4 Infection in a Cohort of Egyptian Patients: An Experiment the Size of Egyptian Village

Efficacy and safety of sofosbuvir&ndash;ledipasvir for treatment of a cohort of Egyptian patients with chronic hepatitis C genotype 4 infection

Effect of cyclosporine A versus tacrolimus on the response to antiviral therapy after hepatitis C genotype‐4 recurrence post–liver transplantation: A prospective cohort trial

Contact Info

Product

Resources

About

Efficacy and safety of sofosbuvir–ledipasvir for treatment of a cohort of Egyptian patients with chronic hepatitis C genotype 4 infection